Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC
Sponsored by Hunan Province Tumor Hospital
About this trial
Last updated 2 years ago
Study ID
CRONUS
Status
Recruiting
Type
Observational
Placebo
No
Accepting
18+ Years
All Sexes
Trial Timing
Ended a year ago
What is this trial about?
This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in HER 2 insertion or amplification.
What are the participation requirements?
Inclusion Criteria
* ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
* HER 2 Insertion or Amplification
* First Diagnosis and Treatment
* Treatment Plan is Chemotherapy or Chemotherapy plus PD-1 antibody
Exclusion Criteria
* Patients received antitumor treatment before
* Patients with contraindication of chemotherapy
* Pregnant or breast feeding women